top of page

Memo’s COVID-19 therapeutic performs on par with leading competitors


Memo Therapeutics's Dropzylla™ platform technology helps to identify therapeutic candidates within six weeks. 


We are delighted to announce that the SARS-CoV2 therapeutic antibody candidate, MTX-COVAB of our portfolio company Memo Therapeutics (Redalpine Capital II) demonstrated outstanding activity in prevention and therapy of SARS-CoV2 infections in hamsters, the common animal model of the infection. 


MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is on par with the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. The scientific data are available here.


Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Over the course of an infection, a patient develops antibodies against the infectious agent. Memo exploits this fact by isolating and manufacturing antibodies from disease survivors for use in patients who cannot overcome such an infection on their own. With their Dropzylla™ platform technology, Memo can identify therapeutic candidates from survivors’ blood within six weeks. 


Memo impressively demonstrated their platform capabilities in June when they identified highly potent virus-neutralizing antibodies from COVID-19 survivors and already in August named a lead candidate, MTX-COVAB, a fully human antibody.


Memo agreed with regulatory authorities on a fast-track development plan for MTX-COVAB and plans to begin clinical studies in 2021.


For more information, please visit Memo’s website.  

Comments


bottom of page